Clinical Scorecard: Rapid WGS Shortens Time to Genomic Reporting in Children With Cancer

At a Glance

Key Highlights

• Average time to a clinically interpretable genomic report was 3 days with rWGS; the average across testing methods overall was 42 days.
• rWGS detected 147 of 155 clinically actionable variants identified by any method; routine WGS detected 138.
• The eight actionable variants missed by rWGS did not change diagnosis or management in the affected patients.
• Among 35 prospectively assessed patients, clinicians reported measurable care improvements in 17, including faster diagnosis or risk stratification and access to precision treatments.
• The study was small, single-center, and non-randomized, and was not designed to establish clinical impact or cost savings.

Guideline-Based Recommendations

Diagnosis

• The study compared rWGS with routine WGS and conventional molecular tests, including fluorescence in situ hybridization, targeted next-generation sequencing, and RNA fusion testing.

Management

• Clinicians reported faster diagnosis and risk stratification, access to precision treatments, and avoidance of unnecessary investigations or therapies among the reported care improvements.
• In some cases, sequencing blood or other samples provided sufficient diagnostic information to avoid more invasive procedures.

Monitoring & Follow-up

• The study reported that rWGS provided measurable residual disease markers; it did not specify a monitoring protocol.

Risks

• The study was not designed to demonstrate clinical impact or cost savings.
• The authors stated that larger multicenter studies are needed to establish reproducibility, cost-effectiveness, and scalability before wider implementation.

Patient & Prescribing Data

The study included 54 children with hematologic malignancies or solid tumors: 35 enrolled prospectively and 19 assessed using archived samples.

Among prospectively assessed patients, clinicians reported measurable care improvements for 17 of 35 (49%). Reported examples included access to precision treatment and avoidance of unnecessary investigations or therapies; the study did not establish comparative treatment outcomes.

Clinical Best Practices

• The study found that rWGS detected 147 of 155 clinically actionable variants identified across all methods; it did not detect every such variant.
• The study reported an average rWGS turnaround of 3 days, compared with 29 days for routine WGS in solid tumors and 63 days in hematologic malignancies.
• The authors noted that the study was not designed to demonstrate clinical impact or cost savings and called for larger multicenter studies to establish reproducibility, cost-effectiveness, and scalability.

Related Resources & Content

• Nature Communications study described in the source article